Lv1
30 积分 2024-03-18 加入
Dual PARP/NAMPT Inhibitors for BRCA Wild-Type Triple-Negative Breast Cancer: Disrupting Homologous Recombination Repair and Activating Antitumor Immunity
1个月前
已完结
Discovery of Tetracyclic Derivatives as Highly Potent, Selective, and Bioavailable PKMYT1 Inhibitors for Cancer Therapy
1个月前
已完结
Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: Synthesis, SAR, and pharmacokinetic properties
1个月前
已完结
Design and Structural Optimization of Orally Bioavailable RSK4 Inhibitors for the Treatment of Esophageal Squamous Cell Carcinoma
1个月前
已完结
Extracellular HSP90-Facilitated Degradation of Extracellular and Membrane Proteins by Bifunctional Small Molecules
2个月前
已完结
Bifunctional LYTAC Mediates Hepatocytes-Hepatic Stellate Cells Crosstalk by Regulating 5-HT2A Receptor Degradation and Antagonism to Synergistically Ameliorate Hepatic Fibrosis
2个月前
已完结
Discovery of dCDK9-202 as a Highly Potent and Selective PROTAC CDK9 Degrader with Strong In Vivo Antitumor Activity
3个月前
已完结
Benzofuranyl-pyrazole as a Novel Scaffold for In Vitro and In Vivo Potent Anticancer Therapeutics That Directly Disrupt the ‘Undruggable’ MYC Oncogene and Potentiate Immune Checkpoint Blockage
4个月前
已完结
Novel Aptamer-Drug Conjugate for Targeted Therapy in Triple-Negative Breast Cancer
4个月前
已完结
Unveiling a novel pyrazolopyrimidine scaffold as a dual COX-2/5-LOX inhibitor with immunomodulatory potential: Design, synthesis, target prediction, anti-inflammatory activity, and ADME-T with docking simulation
5个月前
已完结
皖公网安备34019202002308
